Cancer pain directly affects the patient's quality of life. We have previously demonstrated that the subcutaneous administration of the mammary
adenocarcinoma known as Ehrlich
tumor induces
pain in mice. Several studies have shown that the
flavonoid quercetin presents important biological effects, including anti-inflammatory,
antioxidant,
analgesic, and antitumor activity. Therefore, the
analgesic effect and mechanisms of
quercetin were evaluated in Ehrlich
tumor-induced
cancer pain in mice. Intraperitoneal (i.p.) treatments with
quercetin reduced Ehrlich
tumor-induced mechanical and
thermal hyperalgesia, but not paw thickness or histological alterations, indicating an
analgesic effect without affecting
tumor growth. Regarding the
analgesic mechanisms of
quercetin, it inhibited the production of hyperalgesic
cytokines IL-1β and TNFα and decreased neutrophil recruitment (
myeloperoxidase activity) and oxidative stress.
Naloxone (
opioid receptor antagonist) inhibited
quercetin analgesia without interfering with neutrophil recruitment,
cytokine production, and oxidative stress. Importantly, cotreatment with
morphine and
quercetin at doses that were ineffective as single treatment reduced the nociceptive responses. Concluding,
quercetin reduces the Ehrlich
tumor-induced
cancer pain by reducing the production of hyperalgesic
cytokines, neutrophil recruitment, and oxidative stress as well as by activating an
opioid-dependent
analgesic pathway and potentiation of
morphine analgesia. Thus,
quercetin treatment seems a suitable therapeutic approach for
cancer pain that merits further investigation.